Ukwelashwa kwe-CAR-T kwe-Relapsed/Refractory Neuroblastoma
Mayelana Nokwelashwa
Ukwelashwa kwe-GD2 CAR-Tiwukwelashwa nge-immunotherapy okusha okuguqula izakhi zofuzo zamaseli e-T esiguli ukuze kubonwe futhi kuhlaselwe amaseli e-neuroblastoma aveza i-antigen ye-GD2. Lokhu kwelashwa kwenzelwe ngqo iziguli ezine-neuroblastoma ephinde yabuya noma engaphikisi futhi kubonise imiphumela yezokwelapha ethembisayo ezivivinyweni.
Izindlela Zokufaneleka
-
Isimo Sesifo: I-neuroblastoma eyingozi kakhulu enesifo esiqhubekayo, esibuyela emuva, noma esiqhubekayo ngemva kokwelashwa kokuqala.
-
Ezinye Izinto: Isifo esisakazeka kalula, ukwanda kwe-MYCN, noma ukumelana nemithi yokwelapha evamile.
Inqubo Yokwelapha
Izinyathelo Eziyinhloko
-
Ukulungisa kusengaphambili: Ukuncipha kwe-lymphodepletion ngaphambi kokufakwa.
-
Ukufakwa: Ukulinganisa ngokunembile kwamaseli e-GD2-CAR-T (kunconywa: amaseli e-T angu-10×10^6 ane-CAR/kg).
-
Landelela: Ukuhlolwa kwezithombe njalo (i-PET/CT, i-MRI) kanye nokuhlolwa komnkantsha ngemva kokufakwa.
Ukusebenza kahle nokuphepha
Imiphumela Yezokwelapha
-
Izinga Lokuphendula: Ama-33% athole ukuxolelwa okuphelele (CR), kanye nesilinganiso sokuphendula jikelele (CR+PR) esingu-63%.
-
Ukusinda: ukusinda okuphelele kweminyaka emi-3 (OS) okungu-60% kanye nokusinda okungenazo izigameko (EFS) okungu-36% ngesilinganiso esinconywayo.
-
Iphrofayili Yokuphepha: Izehlakalo ezimbi ezivame kakhulu kwakuyi-Grade 1-2 cytokine release syndrome elawulekayo (74%).
Kungani Sikhethe
Izinzuzo Zethu
-
I-CAR yesizukulwane sesithathu: Izizinda ezimbili ezikhuthazayo (CD28 + 4-1BB) zithuthukisa amandla kanye nokuphikelela kwamaseli e-T.
-
Ukushintsha Kokuphepha: I-gene ehlanganisiwe ye-iC9 ivumela ukulawulwa okusheshayo kobuthi uma kudingeka.
-
Irekhodi Eliqinisekisiwe Lethrekhi: Ubonise impumelelo ezivivinyweni zemitholampilo ngedatha yokulandelela eqinile yesikhathi eside.
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.